37.89

1.47% +0.55

Soleno Therapeutics Inc (SLNO)

Overview News Price History Option Chain Discussions Forecast Stock Split

Soleno Therapeutics Inc stock is currently priced at $37.89, with a 24-hour trading volume of 138.38K. It has seen a +1.47% increased in the last 24 hours and a -12.29% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $37.71 pivot point. If it approaches the $38.16 resistance level, significant changes may occur.

Previous Close:

$37.34

Open:

$37.09

24h Volume:

138.38K

Market Cap:

$1.27B

Revenue:

Net Income/Loss:

$-38.99M

P/E Ratio:

-12.50

EPS:

-3.03

Net Cash Flow:

$-24.94M

1W Performance:

+1.04%

1M Performance:

-12.29%

6M Performance:

+57.94%

1Y Performance:

+988.79%

1D Range:

$37.09

$38.33

52W Range:

$3.16

$53.82

Soleno Therapeutics Inc Stock (SLNO) Company Profile

Name

Soleno Therapeutics Inc

Sector

Healthcare (1191)

Industry

Biotechnology (688)

Phone

650 213 8444

Address

203 Redwood Shores Parkway, Suite 500, Redwood City, CA

Employee

Twitter

Next Earnings Date

2024-05-07

Latest SEC Filings

SLNO's Discussions on Twitter

Soleno Therapeutics Inc Stock (SLNO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-05-24	Initiated	Piper Sandler	Overweight
Jan-23-24	Initiated	Stifel	Buy
Nov-21-23	Resumed	Guggenheim	Buy
Sep-29-20	Initiated	Guggenheim	Buy
Jan-10-20	Initiated	Craig Hallum	Buy
Dec-23-19	Initiated	Oppenheimer	Outperform
Feb-13-18	Reiterated	Maxim Group	Buy

View All

Soleno Therapeutics Inc Stock (SLNO) Latest News

Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc.

Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc.

Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results

GlobeNewswire Inc.

Soleno Therapeutics, Inc. (SLNO) Is a Great Choice for 'Trend' Investors, Here's Why

Zacks Investment Research

Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc.

Here's Why Momentum in Soleno Therapeutics, Inc. (SLNO) Should Keep going

Zacks Investment Research

Soleno Therapeutics Inc Stock (SLNO) Financials Data

Soleno Therapeutics Inc (SLNO) Net Income 2024

SLNO net income (TTM) was -$38.99 million for the quarter ending December 31, 2023, a -62.00% decrease year-over-year.

Soleno Therapeutics Inc (SLNO) Cash Flow 2024

SLNO recorded a free cash flow (TTM) of -$24.94 million for the quarter ending December 31, 2023, a -19.94% decrease year-over-year.

Soleno Therapeutics Inc (SLNO) Earnings per Share 2024

SLNO earnings per share (TTM) was -$2.9966 for the quarter ending December 31, 2023, a +0.77% growth year-over-year.

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.